SGLT-2 inhibitors reduce adverse CV events associated with restenosis in stents in patients with type 2 diabetes.

Published Date: 13 Mar 2023

Italy: Treatment with SGLT2 inhibitors in patients with type 2 diabetes (T2D) is associated with a reduced risk of restenosis in the stent...

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Second Malignancy Risk With CAR T-Cell Therapy on Par With Other Treatments

2.

Obesity linked to subsequent neoplasms in childhood cancer survivors

3.

Are ultramarathon runners really at increased risk of bowel cancer?

4.

Study finds 10% of pediatric blood cancers may stem from medical imaging radiation

5.

'Ticking Time Bomb'; Jimmy Carter's Lasting Impact on Cancer; Breast Cancer-CVD Link


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot